Manager TitleAgeSince
Chief Executive Officer - 01/04/2026
Chief Tech/Sci/R&D Officer - 17/07/2009
Director of Finance/CFO 60 01/07/2022
Director TitleAgeSince
Director/Board Member 58 09/07/2020
Chairman 68 09/12/2021
Director/Board Member 78 01/09/2004
Change 5-day change 1-year change 3-year change Capi.($)
-0.96%-2.29%-40.51%-7.98% 86.72B
+0.64%-1.76%-9.47%-19.50% 35.53B
-0.55%+0.93%+0.77%-18.01% 14.78B
-0.58%+4.38% - - 11.98B
+9.66%+10.58%-9.90%+749.91% 2.53B
-2.64%-6.71%-44.74%-59.11% 1.43B
-1.61%+0.69%+15.64%+8.44% 883M
-0.26%-3.24%+52.72%-8.02% 893M
-0.94%+1.86% - - 878M
Average +0.31%+0.68%-5.07%+92.25% 17.29B
Weighted average by Cap. -0.37%+1.31%-27.08%+1.15%
Logo TearLab Corp
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.
Employees
-